Do peptides help with growth hormone deficiency and GH secretagogue use?
6 peptides are graded for growth hormone deficiency and GH secretagogue use on this page. The strongest grade is human RCT evidence, for tesamorelin, sermorelin, CJC-1295, MK-677 (ibutamoren), and hexarelin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for growth hormone deficiency and GH secretagogue use?
Confirm diagnosis with stimulation testing; recombinant human growth hormone replacement for documented deficiency; treat the underlying cause.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for growth hormone deficiency and GH secretagogue use?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Tesamorelin | Evidence: Human RCT evidence | FDA approved as Egrifta; 15 to 18% reduction in visceral fat over 26 weeks in HIV lipodystrophy trials. [3] |
| Sermorelin | Evidence: Human RCT evidence | Formerly FDA approved (Geref) for pediatric GH deficiency; product withdrawn for commercial reasons; compounded widely. [2] |
| CJC-1295 | Evidence: Human RCT evidence | Small randomized, placebo-controlled studies in healthy adults raised GH and IGF-1 (surrogate endpoints only); no trial in growth hormone deficiency; development halted; FDA lists its nomination as withdrawn (FDA page dated April 22, 2026). [2] |
| MK-677 (ibutamoren) | Evidence: Human RCT evidence | Not a peptide (oral small molecule ghrelin agonist); human trials in older adults; not approved. [2] |
| Hexarelin | Evidence: Human RCT evidence | Three small randomized studies in healthy volunteers found single intravenous doses raise growth hormone; these measured hormone responses over a few hours, not clinical outcomes; in a 16 week study the GH response fell by about half and IGF-1 did not rise; not approved. [2] [6] [7] [8] [9] |
| Ipamorelin | Evidence: Human observational evidence | A pharmacology study in 40 healthy men found a single intravenous infusion releases growth hormone; its one randomized, placebo-controlled trial tested intravenous ipamorelin after bowel surgery (117 patients) and found no benefit; no randomized trial for growth hormone deficiency or the uses it is sold for; development stopped; listed by FDA as a withdrawn 503A nomination since April 2026. [2] [4] [5] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for growth hormone deficiency and GH secretagogue use?
Tesamorelin, sermorelin, CJC-1295, MK-677 (ibutamoren), and hexarelin have the strongest evidence among the peptides graded here, at human RCT evidence. Tesamorelin: FDA approved as Egrifta; 15 to 18% reduction in visceral fat over 26 weeks in HIV lipodystrophy trials. Sermorelin: Formerly FDA approved (Geref) for pediatric GH deficiency; product withdrawn for commercial reasons; compounded widely. CJC-1295: Small randomized, placebo-controlled studies in healthy adults raised GH and IGF-1 (surrogate endpoints only); no trial in growth hormone deficiency; development halted; FDA lists its nomination as withdrawn (FDA page dated April 22, 2026). MK-677 (ibutamoren): Not a peptide (oral small molecule ghrelin agonist); human trials in older adults; not approved. Hexarelin: Three small randomized studies in healthy volunteers found single intravenous doses raise growth hormone; these measured hormone responses over a few hours, not clinical outcomes; in a 16 week study the GH response fell by about half and IGF-1 did not rise; not approved. [2] [3] [6] [7] [8] [9]
Is any peptide FDA approved for growth hormone deficiency and GH secretagogue use?
Tesamorelin is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to growth hormone deficiency and GH secretagogue use. The other peptides graded here are not FDA approved. [3] [10]
Has any peptide been tested in a randomized trial for growth hormone deficiency and GH secretagogue use?
Yes, for tesamorelin, sermorelin, CJC-1295, MK-677 (ibutamoren), and hexarelin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3] [6] [7] [8] [9]
From the blog
- Ipamorelin side effects and benefits: what studies show
Ipamorelin side effects in its one human trial matched placebo, but FDA flags serious events with IV use. Claimed benefits for muscle, fat loss, and sleep are untested. Not FDA approved.
- CJC-1295 side effects, alone and with ipamorelin
CJC-1295 side effects in small human trials included injection site reactions, headache, flushing, and a faster heart rate. The ipamorelin blend is untested. Neither peptide is FDA approved.
- Sermorelin vs HGH: mechanism, evidence, and legal status
Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label.
- Tesamorelin vs HGH: how they differ and which is approved
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
- Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.
Sources
- [1]Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007PubMed 18057338, 2007
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [3]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
- [4]Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersPubMed 10496658, 1999
- [5]Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsPubMed 25331030, 2014
- [6]Growth hormone-releasing activity of hexarelin in humans. A dose-response studyPubMed 7957536, 1994
- [7]The effect of an opiate antagonist on the hormonal changes induced by hexarelinPubMed 7586608, 1995
- [8]Acute administration of hexarelin stimulates GH secretion during day and night in normal menPubMed 9156035, 1997
- [9]Growth hormone status during long-term hexarelin therapyPubMed 9589671, 1998
- [10]Drugs@FDA: FDA-approved drugs databaseFDA